CN1466464A - 癌症治疗药 - Google Patents
癌症治疗药 Download PDFInfo
- Publication number
- CN1466464A CN1466464A CNA018162150A CN01816215A CN1466464A CN 1466464 A CN1466464 A CN 1466464A CN A018162150 A CNA018162150 A CN A018162150A CN 01816215 A CN01816215 A CN 01816215A CN 1466464 A CN1466464 A CN 1466464A
- Authority
- CN
- China
- Prior art keywords
- amrubicin
- cancer
- pharmaceutically acceptable
- acceptable salt
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
CI值 | D1 | D2 | Df1 | Df2 | |
本发明(盐酸氨柔比星醇) | 0.38 | 0.239 | 0.119 | 0.671 | 6.312 |
对照化合物(盐酸阿霉素) | 0.92 | 0.373 | 0.187 | 0.434 | 6.312 |
盐酸氨柔比星醇和Herceptin的用量比 | CI值 | D1 | D2 | Df1 | Df2 |
2∶1 | 0.38 | 0.239 | 0.119 | 0.671 | 6.312 |
4∶1 | 0.33 | 0.212 | 0.053 | 0.671 | 6.312 |
8∶1 | 0.42 | 0.279 | 0.035 | 0.671 | 6.312 |
CI值 | D1 | D2 | Df1 | Df2 | |
本发明(盐酸氨柔比星) | 0.17 | 1.267 | 0.032 | 7.542 | 6.312 |
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP228239/2000 | 2000-07-28 | ||
JP228239/00 | 2000-07-28 | ||
JP2000228239 | 2000-07-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Division CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466464A true CN1466464A (zh) | 2004-01-07 |
CN100581585C CN100581585C (zh) | 2010-01-20 |
Family
ID=18721568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Expired - Fee Related CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
CN01816215A Expired - Fee Related CN100581585C (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Expired - Fee Related CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Country Status (13)
Country | Link |
---|---|
US (3) | US7449181B2 (zh) |
EP (1) | EP1308168B1 (zh) |
JP (1) | JP5117660B2 (zh) |
KR (1) | KR20030019623A (zh) |
CN (2) | CN101732333B (zh) |
AT (1) | ATE397458T1 (zh) |
AU (1) | AU2001276689A1 (zh) |
CA (1) | CA2417255C (zh) |
DE (1) | DE60134324D1 (zh) |
DK (1) | DK1308168T3 (zh) |
ES (1) | ES2307633T3 (zh) |
TW (1) | TWI317285B (zh) |
WO (1) | WO2002009754A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
CN107349426A (zh) * | 2017-07-12 | 2017-11-17 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
US7625859B1 (en) * | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
CN100400046C (zh) * | 2002-03-18 | 2008-07-09 | 大日本住友制药株式会社 | 肺癌治疗药 |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
US20080206231A1 (en) * | 2004-10-05 | 2008-08-28 | Oregon Health And Science University | Compositions and Methods for Treating Disease |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
US9551033B2 (en) * | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2362783A2 (en) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
KR20140057326A (ko) | 2011-08-17 | 2014-05-12 | 제넨테크, 인크. | 뉴레귤린 항체 및 그의 용도 |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6075473A (ja) * | 1983-09-30 | 1985-04-27 | Sumitomo Chem Co Ltd | アミノナフタセン誘導体 |
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5077220A (en) * | 1988-08-26 | 1991-12-31 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells |
JPH035397A (ja) | 1989-05-31 | 1991-01-11 | Toshiba Corp | 酸化物結晶薄膜の気相成長方法 |
JP3005397B2 (ja) | 1993-09-06 | 2000-01-31 | 関西日本電気ソフトウェア株式会社 | デッドロック多発自動回避方式 |
US5686278A (en) * | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
CN1164238A (zh) * | 1994-09-12 | 1997-11-05 | 国际生物免疫有限公司 | 抗人结肠癌相关抗原的单克隆抗体及其应用 |
KR19990082463A (ko) * | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
CN1082187C (zh) * | 1996-11-26 | 2002-04-03 | 北京市肿瘤防治研究所 | 一种检测雌激素受体水平的生物试剂及免疫组化方法 |
KR100565883B1 (ko) * | 1997-01-22 | 2006-03-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 응고 및 종양 치료용 조직 인자 방법 및 조성물 |
US20030068318A1 (en) * | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
-
2001
- 2001-07-24 TW TW90118039A patent/TWI317285B/zh not_active IP Right Cessation
- 2001-07-26 WO PCT/JP2001/006467 patent/WO2002009754A1/ja active IP Right Grant
- 2001-07-26 EP EP20010954360 patent/EP1308168B1/en not_active Expired - Lifetime
- 2001-07-26 ES ES01954360T patent/ES2307633T3/es not_active Expired - Lifetime
- 2001-07-26 AU AU2001276689A patent/AU2001276689A1/en not_active Abandoned
- 2001-07-26 CA CA 2417255 patent/CA2417255C/en not_active Expired - Fee Related
- 2001-07-26 KR KR10-2003-7001194A patent/KR20030019623A/ko not_active Application Discontinuation
- 2001-07-26 CN CN2009102523811A patent/CN101732333B/zh not_active Expired - Fee Related
- 2001-07-26 DE DE60134324T patent/DE60134324D1/de not_active Expired - Lifetime
- 2001-07-26 JP JP2002501211A patent/JP5117660B2/ja not_active Expired - Lifetime
- 2001-07-26 US US10/333,978 patent/US7449181B2/en not_active Expired - Fee Related
- 2001-07-26 CN CN01816215A patent/CN100581585C/zh not_active Expired - Fee Related
- 2001-07-26 AT AT01954360T patent/ATE397458T1/de active
- 2001-07-26 DK DK01954360T patent/DK1308168T3/da active
-
2007
- 2007-06-11 US US11/761,264 patent/US7879327B2/en not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/978,275 patent/US9139658B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
CN107349426A (zh) * | 2017-07-12 | 2017-11-17 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2307633T3 (es) | 2008-12-01 |
CN100581585C (zh) | 2010-01-20 |
EP1308168B1 (en) | 2008-06-04 |
CA2417255C (en) | 2011-08-02 |
WO2002009754A1 (fr) | 2002-02-07 |
US20030157097A1 (en) | 2003-08-21 |
TWI317285B (en) | 2009-11-21 |
ATE397458T1 (de) | 2008-06-15 |
US20110104160A1 (en) | 2011-05-05 |
AU2001276689A1 (en) | 2002-02-13 |
EP1308168A4 (en) | 2004-09-01 |
CN101732333B (zh) | 2012-08-15 |
DE60134324D1 (de) | 2008-07-17 |
US20080031881A1 (en) | 2008-02-07 |
US7879327B2 (en) | 2011-02-01 |
US7449181B2 (en) | 2008-11-11 |
DK1308168T3 (da) | 2008-07-28 |
CN101732333A (zh) | 2010-06-16 |
KR20030019623A (ko) | 2003-03-06 |
CA2417255A1 (en) | 2003-01-24 |
EP1308168A1 (en) | 2003-05-07 |
US9139658B2 (en) | 2015-09-22 |
JP5117660B2 (ja) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1466464A (zh) | 癌症治疗药 | |
US9717730B2 (en) | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | |
EP3581182B1 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
RU2498804C2 (ru) | Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина | |
ZA200107771B (en) | Docetaxel in combination with rhuMAb HER2 for the treatment of cancers. | |
JP2014058572A (ja) | Hki−272とビノレルビンとを含有する抗悪性腫瘍剤の組合せ | |
US20060257400A1 (en) | Combination therapy | |
US20220323470A1 (en) | Composition and use thereof in the manufacture of medicament for treating cancer | |
US20220313652A1 (en) | Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in manufacture of medicament for treating cancer | |
CN112569358B (zh) | 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用 | |
WO2005070026A2 (en) | Drug immunoconjugate combination therapy | |
CN111184740B (zh) | 佐太在制备增强紫杉醇抗癌活性的药物中的应用 | |
CN107921134B (zh) | 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物 | |
CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 | |
CN117281902A (zh) | 一种药物组合物在制备治疗黑色素瘤产品中的应用 | |
CN110960679A (zh) | 一种抗肿瘤的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NIPPO SUMITOMO PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SUMITOMO PHARMACEUTICALS CO., LTD. Effective date: 20060317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060317 Address after: Osaka City, Osaka of Japan Applicant after: Dainippon Sumitomo Pharma Co., Ltd. Address before: Osaka Japan Applicant before: Sumitomo Chemical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100120 Termination date: 20170726 |
|
CF01 | Termination of patent right due to non-payment of annual fee |